FDA approves Sunharbo (asundexian) with antiplatelet therapy to reduce ischemic stroke risk in adults with recent noncardioembolic stroke or high-risk TIA.

Asahi Kasei, Dutch software and blockchain company Circularise, and Furuya Metal have launched a joint demonstration project ...

Diabetes is a silent condition that often causes years of unseen damage before symptoms appear. Endocrinologist Dr Ankia ...

US FDA grants marketing approval to Bayer’s asundexian for secondary stroke risk reduction: Berlin Wednesday, November 11, 2026, 09:00 Hrs [IST] Bayer announced that the US Food ...

Deep mourning for Rebecca Gabrielli, dance teacher on 'Dancing with the Stars'. The teacher, this year paired with Eugenio Finardi, now eliminated from the program, shared a touching farewell letter ...

The bloc of parties led by Gadi Eisenkot, leader of Yashar, presented a series of legislative proposals on the day of the first Knesset meeting after the October 27 elections, including one for the ...

The FDA approves asundexian, the first factor XIa inhibitor, cutting stroke risk 26% and setting a regulatory benchmark for factor XI drug developers.

Commentary: Senior-care facilities are expanding services beyond their walls and bringing them into the community and ...

FDA approves Bayer’s asundexian (Sunharbo), the first Factor XIa inhibitor, for secondary stroke prevention. FDA has granted ...

BayerBayer’s SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S. FDA to Reduce the Risk of Stroke in Adults With Recent Non-Cardioembolic Ischemic ...

Your first part-time job pay stub, your first tax return, resident tax when living alone, NISA, and hometown tax donations. Once you enter society, procedures involving money and taxes arrive without ...

Bayer has secured US FDA marketing approval for Sunharbo (asundexian), tablets, marking a major milestone in stroke ...